Cholesterol Metabolism in Chronic Kidney Disease: Physiology, Pathologic Mechanisms, and Treatment
- PMID: 35503178
- PMCID: PMC11106795
- DOI: 10.1007/978-981-19-0394-6_9
Cholesterol Metabolism in Chronic Kidney Disease: Physiology, Pathologic Mechanisms, and Treatment
Abstract
High plasma levels of lipids and/or lipoproteins are risk factors for atherosclerosis, nonalcoholic fatty liver disease (NAFLD), obesity, and diabetes. These four conditions have also been identified as risk factors leading to the development of chronic kidney disease (CKD). Although many pathways that generate high plasma levels of these factors have been identified, most clinical and physiologic dysfunction results from aberrant assembly and secretion of lipoproteins. The results of several published studies suggest that elevated levels of low-density lipoprotein (LDL)-cholesterol are a risk factor for atherosclerosis, myocardial infarction, coronary artery calcification associated with type 2 diabetes, and NAFLD. Cholesterol metabolism has also been identified as an important pathway contributing to the development of CKD; clinical treatments designed to alter various steps of the cholesterol synthesis and metabolism pathway are currently under study. Cholesterol synthesis and catabolism contribute to a multistep process with pathways that are regulated at the cellular level in renal tissue. Cholesterol metabolism may also be regulated by the balance between the influx and efflux of cholesterol molecules that are capable of crossing the membrane of renal proximal tubular epithelial cells and podocytes. Cellular accumulation of cholesterol can result in lipotoxicity and ultimately kidney dysfunction and failure. Thus, further research focused on cholesterol metabolism pathways will be necessary to improve our understanding of the impact of cholesterol restriction, which is currently a primary intervention recommended for patients with dyslipidemia.
Keywords: Apolipoprotein; Cholesterol accumulation; Cholesterol metabolism; Chronic kidney disease; Lipotoxicity.
© 2022. The Author(s), under exclusive licence to Springer Nature Singapore Pte Ltd.
Figures
Similar articles
-
Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease.J Ren Nutr. 2010 Sep;20(5 Suppl):S35-43. doi: 10.1053/j.jrn.2010.05.010. J Ren Nutr. 2010. PMID: 20797569 Review.
-
Hepatic cholesterol transport and its role in non-alcoholic fatty liver disease and atherosclerosis.Prog Lipid Res. 2021 Jul;83:101109. doi: 10.1016/j.plipres.2021.101109. Epub 2021 Jun 11. Prog Lipid Res. 2021. PMID: 34097928 Review.
-
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.Endocr Pract. 2017 Apr;23(Suppl 2):1-87. doi: 10.4158/EP171764.APPGL. Endocr Pract. 2017. PMID: 28437620
-
Interpreting lipoproteins in nonalcoholic fatty liver disease.Curr Opin Lipidol. 2017 Aug;28(4):355-360. doi: 10.1097/MOL.0000000000000427. Curr Opin Lipidol. 2017. PMID: 28441156 Review.
-
[Diabetic dyslipidaemia and the atherosclerosis].Orv Hetil. 2016 May 8;157(19):746-52. doi: 10.1556/650.2016.30441. Orv Hetil. 2016. PMID: 27133274 Review. Hungarian.
Cited by
-
Network-based machine learning reveals cardiometabolic multimorbidity patterns and modifiable lifestyle factors: a community-focused analysis of NHANES 2015-2018.BMC Public Health. 2025 Jul 3;25(1):2297. doi: 10.1186/s12889-025-23483-9. BMC Public Health. 2025. PMID: 40610956 Free PMC article.
-
Lipid Accumulation and Insulin Resistance: Bridging Metabolic Dysfunction-Associated Fatty Liver Disease and Chronic Kidney Disease.Int J Mol Sci. 2025 Jul 20;26(14):6962. doi: 10.3390/ijms26146962. Int J Mol Sci. 2025. PMID: 40725208 Free PMC article. Review.
-
The Roles of Fatty Acids and Apolipoproteins in the Kidneys.Metabolites. 2022 May 20;12(5):462. doi: 10.3390/metabo12050462. Metabolites. 2022. PMID: 35629966 Free PMC article. Review.
-
A General Review of Methodologies Used in the Determination of Cholesterol (C27H46O) Levels in Foods.Foods. 2023 Dec 10;12(24):4424. doi: 10.3390/foods12244424. Foods. 2023. PMID: 38137228 Free PMC article. Review.
-
The Dual Burden: Exploring Cardiovascular Complications in Chronic Kidney Disease.Biomolecules. 2024 Oct 31;14(11):1393. doi: 10.3390/biom14111393. Biomolecules. 2024. PMID: 39595570 Free PMC article. Review.
References
-
- (1997). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 349, 1857–1863. - PubMed
-
- Afsar B, Yilmaz MI, Siriopol D, Unal HU, Saglam M, Karaman M, Gezer M, Sonmez A, Eyileten T, Aydin I, et al. (2017). Thyroid function and cardiovascular events in chronic kidney disease patients. J Nephrol 30, 235–242. - PubMed
-
- Agrawal S, He JC, and Tharaux PL (2021). Nuclear receptors in podocyte biology and glomerular disease. Nat Rev Nephrol 17, 185–204. - PubMed
-
- Agrawal S, Zaritsky JJ, Fornoni A, and Smoyer WE (2017). Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. Nat Rev Nephrol 14, 70. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical